Calder Biosciences, Inc. products

Calder’s RSV vaccine is locked in the correct, natural shape, and has several-fold higher potency, an improved shelf life, and lower cost of goods by comparison to other such programs in development. We estimate this to be a $5B+ market opportunity.

Calder’ protein engineering technology is based on targeted di-tyrosine (DT) crosslinking, which allows proteins to be locked in desired shapes. We apply this methodology to engineer novel vaccines that are locked in the shapes that elicit the most potently protective antibody responses.

Targeted approach, focused responses. Substantially reduced risk vis-à-vis other modalities. Successful recombinant subunit vaccines elicit the highest. Ab responses; Shingrix vs. Zostavax, Gardasil, HBsAg (Recombivax, Engerix, Heplisav), HAV (Vaqta, Havrix).

Pandemic influenza poses a real and present threat of outbreaks with high fatality rates. Each year, seasonal flu causes: 9M-45M illnesses – causing a substantial loss working days and a major burden on society. 140K-800k hospitalizations - loss of independence, high burden on community and healthcare system. 12K-80k deaths, primarily in the elderly.